Company Filing History:
Years Active: 1985-1987
Title: Colin R Howard: Innovator in Hepatitis B Vaccine Development
Introduction
Colin R Howard is a notable inventor based in Tring, GB, recognized for his contributions to the field of vaccine development. He holds 2 patents related to immunogenically active fragments of the hepatitis B surface antigen. His work has significant implications for the preparation of effective hepatitis B vaccines.
Latest Patents
Howard's latest patents focus on the development of immunogenically active fragments of hepatitis B surface antigen. These fragments include a glycoprotein of molecular weight about 28,000 (gp 28) and a protein of molecular weight about 23,000 (p 23). The fragments are prepared in micelle form that is substantially free from detergent, ensuring they are at least as immunogenic as the unfragmented antigen. The innovative process involves layering the detergent-containing fragmentation product on an aqueous buffer with a sucrose gradient and centrifuging it. This method allows for the recovery of micelles containing both gp 28 and p 23 in a detergent-free form, which is crucial for vaccine preparation.
Career Highlights
Colin R Howard is associated with the National Research Development Corporation, where he has made significant strides in vaccine research. His expertise in the field has led to advancements that enhance the immunogenicity of hepatitis B vaccines.
Collaborations
Howard has collaborated with notable colleagues, including Jacinta Skelly and Arie J Zuckerman, contributing to the collective knowledge and innovation in vaccine development.
Conclusion
Colin R Howard's work in the field of hepatitis B vaccine development showcases his innovative spirit and dedication to improving public health. His patents reflect a commitment to advancing medical science and enhancing vaccine efficacy.